// App-Quantinova.ai

AB0525 (2021) : GUSELKUMAB TREATMENT SHOWS RAPID ONSET OF EFFECT ON COMPONENTS OF AMERICAN COLLEGE OF RHEUMATOLOGY RESPONSE CRITERIA: RESULTS OF 2 RANDOMIZED PHASE 3 TRIALS

Researchers

Presenter

  • P. Nash

Principal Investigators

  • I. McInnes

  • C. T. Ritchlin

  • W. C. Tsai

  • Y. Y. Leung

  • L. S. Tam

  • D. Furtner

  • M. Shawi

  • S. Xu

  • S. Sheng

  • A. Kollmeier

  • A. Deodhar

Medical Centers

  • Griffiths University and University of Queensland, Rheumatology Research Unit, Maroochydore, Australia

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

  • University of Rochester, Allergy/Immunology and Rheumatology, Rochester, United States of America

  • Singapore General Hospital, Duke -NUS Medical School, Rheumatology & Immunology, Singapore, Singapore

  • The Chinese University of Hong Kong, Department of Medicine & Therapeutics, Hong Kong, Hong Kong

  • Janssen, a Division of Jonson & Johnson Pte Ltd., Singapore, Singapore

  • Janssen Scientific Affairs, LLC, Immunology, Spring House, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Janssen Research & Development, LLC, Immunology, San Diego, CA, United States of America

  • Oregon Health & Science University, Division of Arthritis & Rheumatic Diseases, Oregon, United States of America

Locations

  • Australia

  • United Kingdom

  • United States

  • Republic of South Korea

  • Singapore

  • Hong Kong

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory Arthritis

Biomarkers

  • C reactive protein

  • Albumin/creatinine

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved